Well, Hy, I would say that was a different case. As I said in my post, all the potential isn't carrying any weight on the OTC, and last summer it seemed we were imminently going to be off the OTC to the NAZ, where the potential will have more effect.

So I still think my post is reasonable in that we need actual revenues (Excellagen...), assured revenues (vaccine approval/production backed buy a PO...), or increased tangible assets (Excellagen licensing agreement, massive add thru NGIO spin...) to buck us off the OTC, grant reasonably-priced access to capital thru the GNBT S-1, etc.

Until something like that adds a material, measurable value to the company, all the irons in the world could be in our fire, and all the great things can be in the hopper. But we will still be under great pressure from the manipulation of the OTC and lacking the exposure/investability of a major market.

Still bullish, by the way, but I think the timeline could reasonably still be several months out, unless there is a great surprise somewhere with the vaccine, 10-Q, etc.